A vein is a blood vessel that returns blood from the tissues of the body back to the heart. The body has two distinct systems of veins -- superficial and deep. The superficial system is made up of veins that are close to the skin. These are the blood vessels you frequently can see on your hand arms, or legs that can become more prominent when you exercise. The deep system is comprised of veins within the muscles of the body. The two systems are connected by small communicating veins. The body regulates the amount of blood going through both systems as a way of rigidly controlling the body's central temperature.
Deep vein thrombosis (DVT) is a condition wherein a blood clot forms in a vein of the deep system. DVTs can occur anywhere in the body, but are most frequently found in the deep veins of the legs, thighs, and pelvis. They may infrequently arise from the upper extremities usually because of trauma, or from an indwelling catheter (tubing) or device.
Thrombexx ampoule leaflet.pdf
2 hours after needle insertion pre-operatively.
Second dose12 hours after removal of the needle post-operatively.
As early as 5-15 minutes pre-operatively.
Thrombexx should be stopped 12 hours before operation.
Thrombexx inhibits thrombin circulating in the blood (it is not related to body weight) on the other hand, LMWH have 80% distribution in fat which is directly related to body weight.
Not needed in prophylactic dose, PTT is not used to monitor efficacy it is used to monitor complications for bleeding.
Stopping heparin alone is not sufficient, due to the massive activation of Thrombin molecule. Thats why the guidelines always recommend stopping heparins & start treatment with direct thrombin inhibitor.
Thrombexx® cream: As an extension to Rhein-Minapharm's r-Hirudin portfolio, Thrombexx® 1120 I.U cream is introduced for the treatment of hematoma, thrombophlebitis and shunt thrombosis prophylaxis.
Thrombexx® Gel: As an extension to Rhein-Minapharm's r-Hirudin portfolio, Thrombexx® 1120 I.U gel is introduced for the treatment of hematoma, thrombophlebitis and shunt thrombosis prophylaxis.
Minapharm Pharmaceuticals receives regulatory approval from the Paul-Ehrlich Institute for a phase 1 multi-center clinical trial in Germany for its Adalimumab biosimilar
Bioventure, Minapharm Pharmaceuticals and MiGenTra Sign an Exclusive Agreement
for the Commercialization of Multiple Biosimilar Candidates of Alvotech
in the Middle East and Africa
As a global leader in biotechnology & cellular engineering, ProBioGen-Minapharm
As a continuation of Minapharm unique series of "Expert Panel",
The meeting was chaired by Prof. Abdel-Shakour EL MOHAMADY.
The First Netilmicin The Least Resistance
The First Netilmicin Combination the Quick Relief for Ocular Inflammation
Striking Glaucoma Treatment Goals Balancing EFFICACY, COMPLIANCE & AFFORADABILITY
Robust & long lasting correction of serum vitamin D levels For prophylaxis and/or treatment of vitamin D deficiency
Stay connected, subscribe to our newsletter for news and updates.